Skip to main content

Advertisement

ADVERTISEMENT

News

Biotech Company Receives Grant For Infection Study

Arrevus, Inc (Raleigh, NC), a biotechnology company focused on fighting antibiotic resistance, received a $300 000 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The grant will support further research for ARV-1502, a chaperone protein inhibitor with potential to combat antibiotic-resistant infections. Data from a mouse model showed that a single dose of the peptide accelerated wound healing, decreased bacterial burden, and stimulated immune response.​

Visit www.arrevus.com for more information.

Advertisement

Advertisement